Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SILVER-STAR: Sodium zirconium cyclosilicate vs potassium-restricted diet in hyperkalemia with type 2 diabetes mellitus
jRCTs051230067Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of sodium zirconium cyclosilicate in hyperkalemia (2 arms), sponsored by AstraZeneca. Started Nov 2023; status: active, not recruiting.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on jRCTs051230067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051230067.